|
|
|
|
| LEADER |
03246nam a2200361 u 4500 |
| 001 |
EB000943113 |
| 003 |
EBX01000000000000000736703 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Gartlehner, Gerald
|
| 245 |
0 |
0 |
|a Drug class review: Second-generation antidepressants
|h Elektronische Ressource
|b final update 5 report
|c Gerald Gartlehner ... [et al.] ; produced by RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill
|
| 246 |
3 |
1 |
|a Second-generation antidepressants
|
| 260 |
|
|
|a Portland, Oregon
|b Oregon Health & Science University
|c c2011, 2011
|
| 300 |
|
|
|a 1 PDF file (190 p.
|b ill.)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Serotonin Uptake Inhibitors / adverse effects
|
| 653 |
|
|
|a Serotonin Uptake Inhibitors / therapeutic use
|
| 653 |
|
|
|a Antidepressive Agents, Second-Generation / adverse effects
|
| 653 |
|
|
|a Antidepressive Agents, Second-Generation / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 710 |
2 |
|
|a Research Triangle Institute-University of North Carolina Evidence-based Practice Center
|
| 710 |
2 |
|
|a Cecil G. Sheps Center for Health Services Research
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 710 |
2 |
|
|a Oregon Health & Science University
|
| 710 |
2 |
|
|a Drug Effectiveness Review Project
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Drug class reviews
|
| 500 |
|
|
|a "March 2011.". - Title from PDF t.p. (viewed on Sept. 9, 2011)
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK54355
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a PURPOSE: We compared the effectiveness and harms of second-generation antidepressants in the treatment of major depressive disorder (MDD), dysthymia, subsyndromal depression, seasonal affective disorder, generalized anxiety disorder, obsessive compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. DATA SOURCES: We searched PubMed, Embase, PsycINFO, the Cochrane Library, and the International Pharmaceutical Abstracts until September 2010. For additional data we also hand searched reference lists, US Food and Drug Administration medical and statistical reviews and dossiers submitted by pharmaceutical companies. REVIEW METHODS: Study selection, data abstraction, validity assessment, grading the strength of the evidence, and data synthesis were all carried out according to standard Drug Effectiveness Review Project review methods. RESULTS AND CONCLUSIONS: Overall, we found no substantial differences in comparative efficacy and effectiveness of second-generation antidepressants for the treatment of depressive or anxiety disorders. Differences exist in the incidence of specific adverse events and the onset of action. Except for MDD, the evidence is limited to few direct comparisons for most indications. No head-to-head evidence is available for MDD in pediatric populations, dysthymia, subsyndromal depression, seasonal affective disorder, and premenstrual dysphoric disorder
|